Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
NPJ Breast Cancer|August 1, 2017
CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available dataJo Anne Zujewski, Lawrence RubinsteinNeuro-Oncology|March 19, 2016
Creating clinical trial designs that incorporate clinical outcome assessmentsMark R Gilbert, Lawrence Rubinstein, Glenn LesserCancer|February 26, 2020
Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancerYeh Chen Lee, Lisa Wang, Elise C Kohn, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301Helen X Chen, Margaret Mooney, Matthew Boron, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2014
Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trialsPhilip A Philip, Kari Chansky, Michael LeBlanc, et al.Frontiers in Medicine|June 20, 2019
Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination TrialsChanning J Paller, Erich P Huang, Thomas Luechtefeld, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2018
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast CancerAndrew D Seidman, Louise Bordeleau, Louis Fehrenbacher, et al.Cancer Chemotherapy and Pharmacology|November 27, 2023
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumorsArjun Mittra, Geraldine H O' Sullivan Coyne, Jennifer Zlott, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2011
First-line therapy in ovarian cancer trialsTate Thigpen, Andreas duBois, Jessica McAlpine, et al.JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.Pageof 2